MARKET

CWBR

CWBR

CohBar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9060
-0.0093
-1.02%
After Hours: 0.9200 +0.014 +1.55% 18:41 10/26 EDT
OPEN
0.9103
PREV CLOSE
0.9153
HIGH
0.9204
LOW
0.8886
VOLUME
481.68K
TURNOVER
--
52 WEEK HIGH
4.250
52 WEEK LOW
0.8500
MARKET CAP
52.50M
P/E (TTM)
-2.5371
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CohBar Antifibrotic Peptide In Combination With Nintedanib Shows Enhanced Effects In An Idiopathic Pulmonary Fibrosis Model
MENLO PARK, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan,
Benzinga · 14h ago
CohBars CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference
MENLO PARK, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will be a participant
GlobeNewswire · 10/08 14:00
CohBar to Present at the BIO Investor Forum
MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company
GlobeNewswire · 10/05 13:00
CohBar to Present at the H.C. Wainwright 4th Annual NASH Investor Conference
MENLO PARK, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company
GlobeNewswire · 09/29 21:05
CohBar to Present at the Oppenheimer Fall Healthcare, Life Sciences, & MedTech Summit
MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company
GlobeNewswire · 09/10 21:05
Insider Buys CohBar's Stock
Petkevich Misha filed a Form 4 with the SEC on Friday, September 4. The insider bought 11,000 shares of CohBar Inc (NASDAQ:CWBR) at an average price of $1.02. After the transaction, the executive's stake in CohBar Inc. moved to 240,609 shares. Shares of CohBar fell by 3.5% from the previous closing price.
Benzinga · 09/04 15:24
CohBar to Present at the H.C. Wainwright Annual Global Investment Conference
MENLO PARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company
GlobeNewswire · 09/03 12:45
Mid-Afternoon Market Update: Dow Rises 90 Points; Salesforce.com Shares Surge On Upbeat Q2 Results
Toward the end of trading Wednesday, the Dow traded up 0.32% to 28,338.77 while the NASDAQ rose 1.73% to 11,665.03. The S&P also rose, gaining 1.07% to 3,480.35.
Benzinga · 08/26 18:31
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CWBR. Analyze the recent business situations of CohBar through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Institutional Holdings
Institutions: 58
Institutional Holdings: 4.77M
% Owned: 8.23%
Shares Outstanding: 57.95M
TypeInstitutionsShares
Increased
15
1.75M
New
25
710.15K
Decreased
1
3.50K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.51%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
Chairman/Independent Director
Albion Fitzgerald
Chief Executive Officer/Director
Steven Engle
Chief Financial Officer/Treasurer/Secretary
Jeffrey Biunno
Chief Scientific Officer
Kenneth Cundy
Director of Investor Relations/IR Contact Officer
Jordyn Tarazi
Director
Jon Stern
Independent Director
Nir Barzilai
Independent Director
Pinchas Cohen
Independent Director
Phyllis Gardner
Independent Director
David Greenwood
Independent Director
Misha Petkevich
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CWBR
CohBar, Inc. (CohBar), is a clinical stage biotechnology company. The Company is focused on the research and development of mitochondria-based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The Company has discovered more than 100 mitochondrial-derived peptides and is focused on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, cancer, fibrotic diseases including idiopathic pulmonary fibrosis (IPF), type 2 diabetes (T2D), cardiovascular and neurodegenerative diseases. The Company’s lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs that include MBT5 Analogs (CXCR4 Antagonists) for Cancer and Other Disease Indicatio, MBT2 Analogs for Fibrotic Diseases, MBT3 Analog for Cancer Immunotherapy and CB5064 Analogs for Type 2 Diabetes.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of CohBar Inc stock information, including NASDAQ:CWBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CWBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CWBR stock methods without spending real money on the virtual paper trading platform.